Hence, further research is highly warranted to gain insight into the ideal clinical parameters and PSA range to identify tumour manifestations in PSMA-negative PCa with [99mTc]Tc-N4-BTG. This evidence concerns the gene FOLH1 and posterior cortical atrophy.